[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]Good news ! Emilie Faggiani, who leads the cell therapy programme for Parkinson's disease at TreeFrog, was selected to talk at the 30th Annual Meeting of NECTAR. The conference, which brings together world-class experts in the field of...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]We're glad to invite you to the first webinar held by TreeFrog Therapeutics on November 18, at 10 am (EST): Scaling-up iPS-derived cell therapy production while preserving cell quality In this webinar, Kevin Alessandri, our CEO & co-founder, will present data...

The Prix Galien MedStartup was awarded on October 26th in Boston to the French cell therapy biotech TreeFrog Therapeutics in the category “Biopharmaceutical Industry”. TreeFrog Therapeutics received this award for the QC-Stem international consortium, which brings together world-class experts in the quality of induced pluripotent...

TreeFrog Therapeutics, a French biotech leveraging a unique cell manufacturing technology to advance a pipeline cell therapies with mass-market potential, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announce a strategic partnership to...

Following an international career in the pharma industry (GSK, Sanofi, Oenobiol), Jean-Luc Treillou co-founded microbiome company LNC therapeutics in 2011, eventually raising 16.5M€ as CEO & Chairman. In 2018, he co-founded TreeFrog Therapeutics with Maxime Feyeux & Kevin Alessandri, taking in charge governance and investor...

TreeFrog Therapeutics was selected to join the French Tech 120 !   Launched by the French government, this program dedicated to startups in the hyper-growth phase offers unprecedented support to 123 fast-growing companies. By pooling the skills of numerous government agencies, ministries and public services, the French...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="64px"][vc_column_text] TreeFrog Therapeutics-すべての人に細胞治療を(幹細胞治療の会社) [/vc_column_text][vc_empty_space height="64px"][vc_column_text][/vc_column_text][vc_empty_space height="64px"][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="64px"][vc_column_text] C-Stem™:幹細胞のカプセル化のメカニズムについて(TreeFrog Therapeutics) [/vc_column_text][vc_empty_space height="64px"][vc_column_text][/vc_column_text][vc_empty_space height="64px"][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="64px"][vc_column_text] 幹細胞の大量生産のメカニズムについて [/vc_column_text][vc_empty_space height="64px"][vc_column_text][/vc_column_text][vc_empty_space height="64px"][/vc_column][/vc_row][vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_empty_space height="64px"][vc_column_text] C-Stem™:細胞治療のコスト削減のメカニズムについて [/vc_column_text][vc_empty_space height="64px"][vc_column_text][/vc_column_text][vc_empty_space height="64px"][/vc_column][/vc_row]...

Our CSO, Maxime Feyeux, contributed to a roundtable entitled "What breakthrough innovations to develop next-generation bioproduction factories ?" organized by BPI France and Medicen in Paris on October 10th 2019, during the Innogeneration event....

TreeFrog Therapeutics has developed C-Stem™ : a proprietary technology platform for the mass-production of iPSc-based cell therapies. C-Stem™ secures cell quality (100% genomic integrity), volumes (x100 cell amplification per week) and dramatically reduces cell therapy costs (by 10 today, by 100 tomorrow). Learn about C-Stem...